LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 23, 2006--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that the supplemental New Drug Application (sNDA) to expand the indication for CUBICIN(R) (daptomycin for injection) as therapy for the treatment of patients with bacteremia with known or suspected endocarditis caused by Staphylococcus aureus (S. aureus) will be the focus of the next public meeting of the Anti-Infective Drugs Advisory Committee on Monday, March 6 at 8:30 a.m. ET. The Cubicin phase 3 trial included in the sNDA is the first study of its kind in bacteremia and infective endocarditis caused by S. aureus. The meeting will take place at the Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Advisory Committee Conference Room, Rm. 1066, 5360 Fishers Lane, Rockville, MD.